The End of the Elimination Strategy: Decisive Factors towards Sustainable Management of COVID-19 in New Zealand.

COVID-19 New Zealand elimination long-term sustainability strategy

Journal

Epidemiologia (Basel, Switzerland)
ISSN: 2673-3986
Titre abrégé: Epidemiologia (Basel)
Pays: Switzerland
ID NLM: 9918333886406676

Informations de publication

Date de publication:
18 Mar 2022
Historique:
received: 12 01 2022
revised: 05 03 2022
accepted: 14 03 2022
entrez: 23 11 2022
pubmed: 24 11 2022
medline: 24 11 2022
Statut: epublish

Résumé

New Zealand has long been praised for the effectiveness of its COVID-19 elimination strategy. It resulted in fewer COVID-19-related deaths, better economic recovery, and less stringent policy measures within its borders compared with other OECD countries, which opted for mitigation or suppression. However, since September 2021, the rising number of infections has not been contained anymore by the contact tracing and self-isolation system in place and the government has shifted towards a policy strategy similar to suppression to manage the crisis. In this case study, we analyse the factors that led the government to switch policy and discuss why elimination became unsustainable to manage the COVID-19 epidemic in New Zealand. Results showed that the socioeconomic and political factors, along with the appearance of new variants and a delayed vaccination program, were accountable for the switch in strategy. This switch allows the country to better adapt to the evolving nature of the disease and to address the social and economic repercussions of the first year of measures. Our conclusion does not disregard elimination as an appropriate initial strategy to contain this pandemic in the absence of a vaccine or treatment, but rather suggests that borders cannot remain closed for long periods of time without creating social, economical, and political issues.

Identifiants

pubmed: 36417272
pii: epidemiologia3010011
doi: 10.3390/epidemiologia3010011
pmc: PMC9620908
doi:

Types de publication

Journal Article

Langues

eng

Pagination

135-147

Références

Vaccines (Basel). 2021 Oct 04;9(10):
pubmed: 34696240
Virus Evol. 2021 Jun 08;7(2):veab052
pubmed: 34527282
Med J Aust. 2020 Sep;213(5):198-200.e1
pubmed: 32789868
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
Med Law Rev. 2021 Oct 8;29(3):468-496
pubmed: 34562101
N Z Med J. 2021 Jul 9;134(1538):68-76
pubmed: 34239146
Lancet Infect Dis. 2020 Sep;20(9):e238-e244
pubmed: 32628905
BMJ. 2020 Dec 22;371:m4907
pubmed: 33561814
Inform Health Soc Care. 2022 Apr 3;47(2):132-143
pubmed: 34260338
BMJ. 2021 Oct 11;375:n2476
pubmed: 34635487
Milbank Q. 2021 Jun;99(2):426-449
pubmed: 33650737
Health Policy. 2018 Aug;122(8):837-853
pubmed: 29961558
PLoS One. 2021 Mar 24;16(3):e0248892
pubmed: 33760836
N Z Med J. 2021 May 21;134(1535):25-35
pubmed: 34012138
Lancet. 2021 Jun 12;397(10291):2234-2236
pubmed: 33932328
N Z Med J. 2021 Jul 9;134(1538):28-43
pubmed: 34239143
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803

Auteurs

Alicia Blair (A)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Mattia de Pasquale (M)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Valentin Gabeff (V)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Mélanie Rufi (M)

Global Studies Institute, University of Geneva, 1205 Geneva, Switzerland.

Antoine Flahault (A)

Institute of Global Health, University of Geneva, 1202 Geneva, Switzerland.

Classifications MeSH